D.A. Davidson Analyzed J2 Global (JCOM) with $95.0 Target; Shorts at SOSEI COMPANY LTD TOKYO (SOLTF) Lowered By 5.05%

Among 6 analysts covering j2 Global (NASDAQ:JCOM), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. j2 Global has $95 highest and $73 lowest target. $88.60’s average target is 14.31% above currents $77.51 stock price. j2 Global had 12 analyst reports since August 5, 2015 according to SRatingsIntel. Citigroup downgraded j2 Global, Inc. (NASDAQ:JCOM) on Wednesday, January 25 to “Neutral” rating. The rating was maintained by Citigroup on Monday, August 7 with “Neutral”. FBR Capital maintained it with “Mkt Perform” rating and $77 target in Wednesday, August 5 report. The firm earned “Mkt Outperform” rating on Friday, December 18 by JMP Securities. The firm earned “Positive” rating on Monday, August 10 by Susquehanna. As per Friday, April 1, the company rating was upgraded by Citigroup. The firm has “Buy” rating by Citigroup given on Wednesday, August 17. The firm has “Mkt Perform” rating by FBR Capital given on Wednesday, November 4. The stock of j2 Global, Inc. (NASDAQ:JCOM) has “Outperform” rating given on Wednesday, August 31 by Robert W. Baird.

SOSEI COMPANY LTD TOKYO (OTCMKTS:SOLTF) had a decrease of 5.05% in short interest. SOLTF’s SI was 459,000 shares in February as released by FINRA. Its down 5.05% from 483,400 shares previously. The stock decreased 1.70% or $1.86 during the last trading session, reaching $107.39. About 20 shares traded. Sosei Group Corporation (OTCMKTS:SOLTF) has 0.00% since February 4, 2017 and is . It has underperformed by 16.70% the S&P500.

j2 Global, Inc., together with its subsidiaries, engages in the provision of Internet services worldwide. The company has market cap of $3.75 billion. It operates through two divisions, Business Cloud Services and Digital Media. It has a 28.75 P/E ratio. The Business Cloud Services segment offers cloud services to sole proprietors, small to medium-sized businesses and enterprises, and government organizations.

Analysts await j2 Global, Inc. (NASDAQ:JCOM) to report earnings on February, 8. They expect $1.69 earnings per share, up 14.97% or $0.22 from last year’s $1.47 per share. JCOM’s profit will be $81.81 million for 11.47 P/E if the $1.69 EPS becomes a reality. After $1.27 actual earnings per share reported by j2 Global, Inc. for the previous quarter, Wall Street now forecasts 33.07% EPS growth.

Since January 16, 2018, it had 0 insider buys, and 1 sale for $232,900 activity. 3,000 shares were sold by Shah Vivek, worth $232,900 on Tuesday, January 16.

The stock decreased 2.36% or $1.87 during the last trading session, reaching $77.51. About 283,261 shares traded. j2 Global, Inc. (NASDAQ:JCOM) has risen 30.53% since February 4, 2017 and is uptrending. It has outperformed by 13.83% the S&P500.

Investors sentiment increased to 1.24 in 2017 Q3. Its up 0.16, from 1.08 in 2017Q2. It is positive, as 29 investors sold j2 Global, Inc. shares while 74 reduced holdings. 35 funds opened positions while 93 raised stakes. 46.29 million shares or 0.55% less from 46.55 million shares in 2017Q2 were reported. Opus Capital Gp Limited Liability Co holds 0.62% or 36,751 shares in its portfolio. Tompkins Financial invested in 65 shares. Regions Finance owns 9,643 shares for 0.01% of their portfolio. Cornerstone Capital Mngmt Lc holds 0% or 7,962 shares in its portfolio. Orrstown Svcs Incorporated reported 0.01% stake. 15,720 are owned by Gsa Ptnrs Llp. Savings Bank Of Mellon owns 725,098 shares or 0.01% of their US portfolio. California Employees Retirement Systems stated it has 0.01% in j2 Global, Inc. (NASDAQ:JCOM). Wellington Management Gru Limited Liability Partnership holds 0.01% or 544,711 shares. Profund Advsrs Lc has 33,420 shares for 0.1% of their portfolio. Nuveen Asset Mngmt Limited Company reported 0.01% in j2 Global, Inc. (NASDAQ:JCOM). Panagora Asset owns 1,275 shares for 0% of their portfolio. Arrowgrass Ptnrs (Us) Ltd Partnership holds 0.14% or 263,561 shares. 28,352 were accumulated by Amp. Axa reported 81,600 shares.

Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. The company has market cap of $2.02 billion. The Company’s marketed products include Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease ; Ultibro/QVA149, an inhalation capsule for the bronchodilator treatment of COPD; and NorLevo, an oral emergency contraceptive. It currently has negative earnings. The companyÂ’s product pipeline consists of SO-1105, an antifungal agent, which is in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious eye diseases, such as cornea and conjunctivitis, and inflammation.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: